Swipe om te navigeren naar een ander artikel
Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX.
Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores.
During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment.
While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
McCahill, L. E., Yothers, G., Sharif, S., Petrelli, N. J., Lai, L. L., Bechar, N., et al. (2012). Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. Journal of Clinical Oncology, 30(26), 3223–3228. CrossRefPubMedPubMedCentral
Post, M. W. (2014). Definitions of quality of life: What has happened and how to move on. Topics in Spinal Cord Injury and Rehabilitation, 20(3), 167–180. CrossRef
Khanna, D., & Tsevat, J. (2007). Health related quality of life: An introduction. American Journal of Managed Care, 13(9), S218–S223. PubMed
Group, T. E. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. CrossRefPubMed
Lin, X.-J., Lin, I. M., & Fan, S.-Y. (2013). Methodological issues in measuring health-related quality of life. Tzu Chi Medical Journal, 25(1), 8–12. CrossRef
Luckett, T., King, M. T., Butow, P. N., Oguchi, M., Rankin, N., Price, M. A., et al. (2011). Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Annals of Oncology, 22(10), 2179–2190. CrossRefPubMed
Watanabe, M., & Eto, K. (2015). Trends in clinical use of targeted therapy for gastrointestinal cancers. Journal of Cancer Metastasis and Treatment, 1(3), 163–171. CrossRef
Polat, U., Arpaci, A., Demir, S., Erdal, S., & Yalcin, S. (2014). Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: Impact of patient education before treatment initiation. Journal of Gastrointestinal Oncology, 5(4), 270–275. PubMedPubMedCentral
Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., et al. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191–3198. CrossRefPubMed
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29(30), 3968–3976. CrossRefPubMed
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., et al. (2008). EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(14), 2311–2319. CrossRefPubMed
Al-Batran, S. E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., et al. (2016). Quality- of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 27(4), 673–679. CrossRefPubMedPubMedCentral
Al-Batran, S. E., & Ajani, J. A. (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116(11), 2511–2518. PubMed
Hsueh-Wen, C., Li-Yin, C., Sheng-Miauh, H., Chen-Jeng, T., & Chen-Jei, T. (2016). Changes in symptom patterns and health related quality of life of cancer patients before and after chemotherapy. Journal of Traditional Chinese Medicine, 36(3), 326–331. CrossRef
Ai, Z.-P., Gao, X.-L., Li, J.-F., Zhou, J.-R., & Wu, Y.-F. (2017). Changing trends and influencing factors of the quality of life of chemotherapy patients with breast cancer. Chinese Nursing Research, 4(1), 18–23. CrossRef
Karnofsky, D., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948). The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer, 1(4), 634–656. CrossRef
Ferrell, B. R. (1995). The impact of pain on quality of life. A decade of research. Nursing Clinics of North America, 30(4), 609–624. PubMed
Enders, C. K. (2010). Applied missing data analysis. New York: Guilford Press.
McKnight, P. E., McKnight, K. M., Sidani, S., & Figueredo, A. J. (2007). Missing data: A gentle introduction. New York: Guildford Press.
Schafer, J. L. (1997). Analysis of incomplete multivariate data. Boca Raton: Chapman & Hall/CRC. CrossRef
Singer, J. D., & Willett, J. B. (2003). Applied longitudinal data analysis: Modeling change and event occurence (1st ed.). New York: Oxford University Press. CrossRef
Hox, J. J. (2010). Multilevel analysis: Techniques and applications (2nd ed.). New York: Routledge Academic: Taylor & Francis Group. CrossRef
Effron, B. (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296. CrossRef
Wehrens, R., Putter, H., & Buydens, L. M. C. (2000). The bootstrap: A tutorial. Chemometrics and Intelligent Laboratory Systems, 51(1), 35–52. CrossRef
Wood, M. (2005). Bootstrapped confidence intervals as an approach to statistical inference. Organizational Research Methods, 8(4), 454–470. CrossRef
Osaba, D. (1999). Interpreting the meaningfulness of changes in health-related quality of life scores: Lessons from studies in adults. International Journal of Cancer, 83(S12), 132–137. CrossRef
Giesinger, J. M., Wintner, L. M., Zabernigg, A., Gamper, E. M., Oberguggenberger, A. S., Sztankay, M. J., et al. (2014). Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer, 14(758), 1–7.
Jansen, L., Hoffmeister, M., Chang-Claude, J., Koch, M., Brenner, H., & Arndt, V. (2011). Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: A population-based prospective cohort. The Oncologist, 16, 1741–1751. CrossRefPubMedPubMedCentral
Schwartz, C. E., & Sprangers, M. A. G. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science & Medicine, 48(11), 1531–1548. CrossRef
- Quality of life of patients with gastrointestinal cancers undergoing chemotherapy
Ilufredo Y. Tantoy
Bruce A. Cooper
Steven M. Paul
Yvette P. Conley
Kord M. Kober
Jon D. Levine
- Springer International Publishing